|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
34,000,000 |
Market
Cap: |
N/A |
Last
Volume: |
18,050 |
Avg
Vol: |
18,000 |
52
Week Range: |
$238.6 - $238.6 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baker Bros. Advisors (gp) Llc |
Director |
|
2015-01-07 |
4 |
B |
$94.19 |
$94,190,000 |
I/I |
1,000,000 |
9,184,771 |
2.25 |
- |
|
Heberlig Chris |
Group Vice President, Finance |
|
2014-12-29 |
4 |
AS |
$89.90 |
$555,971 |
D/D |
(6,100) |
304 |
|
- |
|
Heberlig Chris |
Group Vice President, Finance |
|
2014-12-29 |
4 |
OE |
$1.70 |
$116,870 |
D/D |
6,100 |
6,404 |
|
- |
|
Patel Sanj K |
President & CEO |
|
2014-12-17 |
4 |
AS |
$87.25 |
$4,442,363 |
D/D |
(50,000) |
1,031 |
|
- |
|
Patel Sanj K |
President & CEO |
|
2014-12-17 |
4 |
OE |
$1.70 |
$763,972 |
D/D |
50,000 |
51,031 |
|
- |
|
Boess Carsten |
SVP, Chief Financial Officer |
|
2014-10-30 |
4 |
AS |
$80.11 |
$1,834,839 |
D/D |
(22,904) |
0 |
|
- |
|
Boess Carsten |
SVP, Chief Financial Officer |
|
2014-10-30 |
4 |
OE |
$1.70 |
$206,227 |
D/D |
22,904 |
22,904 |
|
- |
|
Boess Carsten |
SVP, Chief Financial Officer |
|
2014-10-28 |
4 |
AS |
$80.00 |
$200,000 |
D/D |
(2,500) |
0 |
|
- |
|
Boess Carsten |
SVP, Chief Financial Officer |
|
2014-10-28 |
4 |
OE |
$1.70 |
$25,550 |
D/D |
2,500 |
2,500 |
|
- |
|
Bazemore Robert B |
Chief Operating Officer |
|
2014-09-23 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-09-19 |
4 |
AS |
$65.24 |
$51,540 |
D/D |
(790) |
562 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-09-19 |
4 |
OE |
$8.73 |
$6,897 |
D/D |
790 |
1,352 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-09-17 |
4 |
AS |
$65.06 |
$273,252 |
D/D |
(4,200) |
562 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-09-17 |
4 |
OE |
$8.73 |
$36,666 |
D/D |
4,200 |
4,762 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-09-16 |
4 |
AS |
$65.01 |
$609,729 |
D/D |
(9,379) |
562 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-09-16 |
4 |
OE |
$8.73 |
$81,879 |
D/D |
9,379 |
9,941 |
|
- |
|
Quinn Anthony |
EVP, CMO & Head of R&D |
|
2014-09-02 |
4 |
AS |
$69.88 |
$701,404 |
D/D |
(10,000) |
25,595 |
|
- |
|
Quinn Anthony |
EVP, CMO & Head of R&D |
|
2014-09-02 |
4 |
OE |
$23.00 |
$230,000 |
D/D |
10,000 |
35,595 |
|
- |
|
Williams Glen |
SVP, Technical Operations |
|
2014-06-30 |
4 |
A |
$54.89 |
$6,422 |
D/D |
117 |
383 |
|
- |
|
Goldberg Mark Alan |
EVP, Medical & Reg. Strategy |
|
2014-06-30 |
4 |
A |
$54.89 |
$5,654 |
D/D |
103 |
562 |
|
- |
|
Heberlig Chris |
Group Vice President, Finance |
|
2014-06-30 |
4 |
A |
$54.89 |
$6,148 |
D/D |
112 |
304 |
|
- |
|
Quinn Anthony |
EVP, CMO & Head of R&D |
|
2014-06-30 |
4 |
A |
$54.89 |
$3,897 |
D/D |
71 |
25,595 |
|
- |
|
Williams Glen |
SVP, Technical Operations |
|
2014-06-25 |
4 |
AS |
$108.02 |
$75,614 |
D/D |
(700) |
266 |
|
- |
|
Williams Glen |
SVP, Technical Operations |
|
2014-06-25 |
4 |
OE |
$40.32 |
$35,120 |
D/D |
700 |
966 |
|
- |
|
Quart Barry D |
|
|
2014-06-20 |
4 |
AS |
$100.00 |
$137,500 |
D/D |
(1,375) |
0 |
|
- |
|
372 Records found
|
|
Page 3 of 15 |
|
|